Pramipexole ER vs. Placebo in Fibromyalgia
Public ClinicalTrials.gov record NCT00689052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Dose Titration Efficacy and Safety Study of Pramipexole ER (0.75 to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients Diagnosed With Fibromyalgia, as Assessed by the American College of Rheumatology (ACR) Criteria Followed by a 24-week Open-label Extension Phase
Study identification
- NCT ID
- NCT00689052
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- pramipexole ER Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2008
- Primary completion
- Oct 31, 2008
- Completion
- Not listed
- Last update posted
- Jun 8, 2014
Started 2008
United States locations
- U.S. sites
- 42
- U.S. states
- 27
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.637.01009 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 248.637.01033 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 248.637.01045 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 248.637.01034 Boehringer Ingelheim Investigational Site | Hot Springs | Arkansas | — | — |
| 248.637.01032 Boehringer Ingelheim Investigational Site | Arcadia | California | — | — |
| 248.637.01044 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 248.637.01036 Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| 248.637.01042 Boehringer Ingelheim Investigational Site | Englewood | Colorado | — | — |
| 248.637.01031 Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| 248.637.01035 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 248.637.01023 Boehringer Ingelheim Investigational Site | Fort Myers | Florida | — | — |
| 248.637.01047 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 248.637.01043 Boehringer Ingelheim Investigational Site | Palm Beach Gardens | Florida | — | — |
| 248.637.01040 Boehringer Ingelheim Investigational Site | Sunrise | Florida | — | — |
| 248.637.01027 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.637.01007 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 248.637.01028 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.637.01010 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 248.637.01016 Boehringer Ingelheim Investigational Site | Newton | Massachusetts | — | — |
| 248.637.01014 Boehringer Ingelheim Investigational Site | Lansing | Michigan | — | — |
| 248.637.01020 Boehringer Ingelheim Investigational Site | Flowood | Mississippi | — | — |
| 248.637.01018 Boehringer Ingelheim Investigational Site | Picayune | Mississippi | — | — |
| 248.637.01012 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 248.637.01017 Boehringer Ingelheim Investigational Site | Billings | Montana | — | — |
| 248.637.01024 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 248.637.01008 Boehringer Ingelheim Investigational Site | Albany | New York | — | — |
| 248.637.01002 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.637.01025 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 248.637.01026 Boehringer Ingelheim Investigational Site | Fargo | North Dakota | — | — |
| 248.637.01004 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 248.637.01038 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 248.637.01003 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 248.637.01046 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 248.637.01006 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 248.637.01039 Boehringer Ingelheim Investigational Site | Duncansville | Pennsylvania | — | — |
| 248.637.01015 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | — | — |
| 248.637.01019 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 248.637.01037 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 248.637.01041 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 248.637.01021 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 248.637.01029 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| 248.637.01011 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00689052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00689052 live on ClinicalTrials.gov.